Building the next category-defining molecular diagnostics platform.
Kihealth is developing a scalable molecular diagnostics platform positioned at the intersection of precision medicine, preventative healthcare, metabolic disease, and AI-driven biomarker intelligence.
A generational market. A single molecular platform built to serve it.
Kihealth is positioned at the intersection of the world's largest and fastest-growing chronic disease markets — with a scalable platform designed to compound advantage across every vertical it enters.
One molecular intelligence platform — powering an expanding portfolio of disease-interception diagnostics.
A precision diagnostics company built on one molecular intelligence platform.
Kihealth Labs is a clinical-stage molecular intelligence diagnostics company operating a high-complexity CLIA laboratory and advancing a multi-disease pipeline on the Intercept IQ™ platform.
Building the Infrastructure for Earlier Disease Intelligence
Kihealth Labs is developing an integrated laboratory, data, and AI platform designed to measure active disease biology earlier and support more precise decisions across clinical care, diagnostic development, and therapeutic research.
Earlier Biological Insight
Identify meaningful biological changes before advanced disease progression creates fewer opportunities for intervention.
Multi-Application Platform
Use one integrated laboratory and intelligence infrastructure to support multiple diagnostic, research, and therapeutic applications.
Multiple Revenue Pathways
Create opportunities across clinical testing, pharmaceutical services, research programs, enterprise partnerships, and technology licensing.
Expanding Evidence Base
Build clinical and scientific validation through active studies, academic collaborations, and pharmaceutical partnerships.
Precision Medicine Needs a Clearer View of Active Disease Biology
Many diseases develop through measurable biological changes before symptoms become apparent or conventional diagnostic thresholds are reached. Yet laboratory, clinical, and longitudinal data often remain fragmented, limiting the ability to recognize meaningful patterns and changing risk.
Current Gap
Biology precedes symptoms.
Late Recognition
Disease is often identified after meaningful biological progression has already occurred.
Fragmented Data
Laboratory results, clinical information, and longitudinal changes are frequently evaluated separately.
Isolated Measurements
Individual biomarkers may provide an incomplete view of complex disease biology.
Limited Patient Stratification
Physicians, researchers, and drug developers need better tools to identify and understand distinct risk profiles.
The Window for Earlier Intervention Closes Long Before Diagnosis
Intercept IQ is designed to operate in the interval where biological signal is detectable but disease burden is still modifiable.
Early Biological Change
Detectable Signals
Actionable
Increasing Risk
Actionable
Clinical Symptoms
Actionable
Diagnosis
The Kihealth Response
A single platform that unifies molecular signal, clinical context, and longitudinal intelligence.
From Blood Sample to Actionable Health Intelligence
Kihealth Labs combines advanced biomarker testing with the Intercept IQ™ platform and Ki Intelligence to transform complex laboratory and clinical data into a clearer, more integrated understanding of active disease biology and evolving risk.
Blood Sample
Laboratory Analysis
Biomarker Data
Intercept IQ™
Ki Intelligence
Risk Modeling
Intercept Score and Clinical Insight
Blood Sample
Laboratory Analysis
Biomarker Data
Intercept IQ™
Ki Intelligence
Risk Modeling
Intercept Score and Clinical Insight
Kihealth Labs
Generates high-quality laboratory and biomarker data through advanced testing and controlled scientific workflows.
Intercept IQ™
Integrates laboratory results with relevant clinical, demographic, and longitudinal information.
Ki Intelligence
Evaluates patterns and relationships across the data to support validated risk models.
Intercept Score
Translates complex biological information into an interpretable assessment designed to support more informed decisions.
Supporting Better Decisions Across Care and Research
The Kihealth platform transforms complex laboratory and biomarker data into structured biological intelligence that can support clinical decision-making, scientific research, and therapeutic development.
For Physicians
Provide a clearer and more integrated view of patient biology to support:
- Earlier visibility into emerging risk
- Improved patient stratification
- Integrated interpretation of multiple biomarkers
- Longitudinal monitoring of changing risk
- More informed referral and follow-up decisions
- Clearer patient communication
For Researchers and Therapeutic Developers
Provide laboratory, biomarker, and analytical capabilities to support:
- Biomarker discovery and validation
- Patient identification and stratification
- Clinical-study design and execution
- Treatment-response monitoring
- Specialized laboratory services
- Integrated data and analytical support
Kihealth technologies are designed to support—not replace—professional clinical judgment. Capabilities and intended uses may vary by product, clinical validation, population, and regulatory status.
One Platform. Every Layer of Disease Interception.
Intercept IQ is Kihealth's scalable molecular intelligence platform. Each diagnostic application shares the same scientific infrastructure — enabling faster development, lower incremental costs, and expansion into additional disease areas over time.
Every diagnostic, built on the same molecular intelligence core.
Each product below is an extension of the Intercept IQ platform — not a separate one-off assay. New diseases. Same engine.
Early autoimmune beta-cell injury detection for earlier identification, monitoring, and intervention in Type 1 diabetes.
Early cancer detection beginning with pancreatic cancer, with a growing future oncology pipeline.
Beta-cell dysfunction detection and GLP-1 therapy monitoring across metabolic disease and Type 2 diabetes.
Alzheimer's disease and broader CNS biomarker detection — future neurodegenerative applications.
One platform. Every layer of disease interception.
Hover any layer to follow the flow of molecular data through the Intercept IQ™ platform.
A single blood draw enters the platform.
CLIA-grade workflows preserve picogram-level molecular signals.
Multi-task models calibrated against clinical ground truth.
The unified intelligence layer powering every Kihealth product.
Translating molecular intelligence into outcomes at every scale.
A repeatable scientific pipeline turning molecular discoveries into clinically validated diagnostics.
From Biomarker Discovery to Clinical Launch.
A repeatable five-stage pipeline that turns molecular discoveries into clinically validated diagnostics. Every product Kihealth builds moves through the same scientific infrastructure — compounding speed, evidence, and capital efficiency with each launch.
Biomarker Discovery
Identify novel molecular biomarkers associated with disease onset and progression using whole-genome methylation and fragmentomic profiling.
- Timeline
- 1–2 Years
- Research Samples
- 100–300 Samples
Biomarker Validation
Confirm biomarker reproducibility and biological significance across independent patient cohorts before advancing into assay development.
- Timeline
- 6–12 Months
- Validation Cohort
- 300–500 Samples
Assay Development
Develop and analytically validate a robust molecular assay — including ddPCR and targeted NGS workflows — suitable for clinical use.
- Timeline
- ~6 Months
- Output
- Clinical-grade assay
Clinical Validation
Demonstrate analytical performance and clinical utility across diverse patient populations under CLIA / CAP standards.
- Timeline
- 12–24 Months
- Clinical Samples
- 500–1,500 Patients
Clinical Launch
Deploy validated assays through Kihealth's CLIA-certified laboratory and commercial partnerships for real-world patient impact.
- Timeline
- 6–12 Months
- Commercial Validation
- 1,000+ Clinical Samples
Every assay runs on the same scientific infrastructure — Intercept IQ.
Each new program reuses chemistry, automation, and AI — reducing incremental cost.
Diabetes, oncology, and neurodegeneration today. New indications tomorrow.
One platform. A pipeline of products. Decades of compounding value.
Building a Platform Company — Not a Single-Product Company.
Traditional diagnostics companies rely on a single assay and a single market. Kihealth is building a scalable molecular intelligence platform capable of producing multiple diagnostics across metabolic disease, oncology, neuroscience, and future therapeutic areas. Investors are backing a platform that can continuously generate new products — not a single commercial opportunity.
Platform Advantage
Every future diagnostic leverages the same molecular intelligence platform — accelerating speed-to-market and compounding clinical performance.
Scalable Economics
New products become faster and less expensive to develop as the platform expands — each indication amortizes shared R&D investment.
Shared Clinical Infrastructure
Lab, bioinformatics, clinical ops, regulatory, commercial, and AI support every vertical simultaneously.
Expanding Data Moat
Every patient strengthens the platform through proprietary longitudinal molecular datasets — network effects in clinical truth.
Multiple Revenue Streams
Clinical diagnostics, research, clinical trials, pharma partnerships, companion Dx, population screening, employer programs, licensing, international, AI software.
Capital Efficient Expansion
Each new disease indication expands value without rebuilding infrastructure — capital efficiency that traditional diagnostics companies cannot match.
Engineered for clinical scale, regulatory rigor, and commercial reach.
From Core Platform to Commercial Applications.
A purpose-built technology stack engineered for scale — regulatory, payer, and enterprise-ready from day one. The same Intercept IQ core feeds every clinical, commercial, and pharma application above it.
Applications
Intercept IQ™ AI Platform
Proprietary Data & Technology
Patient & Healthcare System
One of the largest opportunities in modern healthcare.
Every Intercept IQ™ vertical attaches the platform to a multi-billion-dollar market — and every Kihealth company multiplies the addressable opportunity.
The macro tailwinds
behind the platform.
Kihealth sits at the intersection of the largest, fastest-growing forces in modern medicine — precision diagnostics, GLP-1 expansion, the global diabetes epidemic, and the shift from reactive care to prediction and prevention.
Precision medicine is the fastest-growing segment of healthcare.
Individualized, molecular-driven care is replacing one-size-fits-all treatment paradigms. Payers, providers, and patients are aligning around biomarker-driven decision making.
GLP-1s are reshaping metabolic care at unprecedented scale.
Tens of millions of new patients are entering long-term GLP-1 therapy. Companion diagnostics and longitudinal beta-cell monitoring become increasingly valuable as therapy selection, response, and durability drive outcomes.
Diabetes is on track to affect 800M+ people globally by 2050.
Diabetes is one of the fastest-expanding chronic conditions worldwide — driving trillions in downstream cost. Earlier detection at the beta-cell level fundamentally changes outcomes and economics.
Healthcare is shifting from reactive treatment to prediction and prevention.
Value-based care, employer risk pools, and payer economics are all realigning around predicting disease early and intervening before irreversible damage. Molecular monitoring is the technology enabler.
A platform at the convergence of every major healthcare megatrend.
Kihealth is building a diagnostics platform positioned at the intersection of the forces reshaping medicine — creating a uniquely attractive opportunity to build a category-defining company against one of the largest unmet needs in healthcare.
Earlier detection. Better decisions. Improved outcomes — at scale.
$1.68 trillion of implied cumulative healthcare-AI related spending between 2026 and 2033 — and Intercept IQ™ is built for it.
Independent research projects the healthcare-AI market growing from $50.7B in 2026 to $505.59B by 2033. Summed across that trajectory, the implied cumulative spend is roughly $1.68 trillion — capital already flowing into laboratory capacity, genomic infrastructure, molecular diagnostics, and clinical decision systems.
The segments Kihealth operates in sit directly inside that spend: molecular diagnostics ($25.6B by 2033), AI in genomics ($18.8B), digital biomarkers ($18.7B), laboratory automation ($18.4B), and multiomics ($9.8B). Every dollar that flows into these categories is demand for a platform that already integrates specimen handling, methylation analytics, AI interpretation, and clinical reporting under one system.
While competitors must assemble these capabilities through acquisition or bolt-on integration, Kihealth ships a single, validated pipeline — turning projected addressable market into platform revenue with a fraction of the build risk.
The $1.68T figure is a Kihealth Labs analysis: it sums annual healthcare-AI market revenue across 2026–2033 along the published growth path from $50.7B (2026) to $505.59B (2033). It is an implied cumulative spending estimate, not a single published market size. Segment figures below are reported as published by their respective research firms and represent total market revenue forecasts — not Kihealth's contracted share. Digital biomarkers are used as the closest measurable proxy for continuous and longitudinal biomarker programs.
Healthcare AI Market — $50.7B (2026) growing to $505.59B by 2033
Grand View ResearchDigital Biomarkers Market — projected $18.7B by 2033
Persistence Market ResearchMarket figures are third-party estimates and are not guarantees of future results. Kihealth Labs is not affiliated with the cited publishers. This page is maintained by Kihealth Labs to answer common investor questions and does not constitute independent verification.
From reactive cost center to predictive value engine.
Healthcare's largest cost burdens come from late-stage disease. Intercept IQ™ shifts the economics — predicting and preventing disease before it becomes the system's biggest expense.
Reactive Medicine
- 01Reactive MedicineCare begins only after symptoms appear.
- 02Symptom-Based CarePatients seek help when damage is already underway.
- 03Laboratory ConfirmationDiagnostics confirm what clinicians already suspect.
- 04TreatmentIntervention arrives late — at higher cost and lower efficacy.
Intercept IQ Platform
- 01Comprehensive Molecular PlatformA single integrated pipeline spanning specimen, methylation, AI, and reporting.
- 02Continuous Molecular MonitoringOngoing, longitudinal tracking of disease biology over time.
- 03AI PredictionMachine-intelligence models forecast risk before clinical onset.
- 04Risk StratificationPatients are triaged by molecular risk, not guesswork.
- 05Earlier InterventionTherapeutic action begins in the window where it still changes outcomes.
- 06PreventionDisease is intercepted before it becomes a cost burden.
- 07Improved OutcomesBetter lives, lower system cost — at population scale.
Built on the Intercept IQ™ Platform
One platform. Multiple high-value verticals.
Every company expands the addressable market.
The Kihealth ecosystem transforms a single core diagnostic platform into multiple high-value, disease-specific businesses. Each portfolio company expands the commercial opportunity, strengthens the proprietary data network, and increases the long-term value of the overall platform — creating multiple paths to growth while leveraging the same underlying technology.
Where we are. Where we’re going.
A single, continuous roadmap across science, platform, and commercialization — each phase building on the last.
Foundation
Company formation, Intercept IQ™ platform architecture, and founding scientific program.
Platform & Clinical Validation
ADA Innovation of the Year, Beta Intercept™ T1D and T2D validation, Ki Intelligence layer.
Commercial Launch
Beta Intercept™ commercial deployment, provider network expansion, first revenue milestones.
Multi-Disease Expansion
Onco Intercept™ and Neuro Intercept™ programs, Kihealth Europe activation, global scale.
Foundation
Company formation, Intercept IQ™ platform architecture, and founding scientific program.
Platform & Clinical Validation
ADA Innovation of the Year, Beta Intercept™ T1D and T2D validation, Ki Intelligence layer.
Commercial Launch
Beta Intercept™ commercial deployment, provider network expansion, first revenue milestones.
Multi-Disease Expansion
Onco Intercept™ and Neuro Intercept™ programs, Kihealth Europe activation, global scale.
Milestones achieved & underway
- Recognition2025
ADA Innovation of the Year
American Diabetes Association recognition for Beta Intercept™ — validating the science and the clinical need.
- Platform2026
Intercept IQ™ Platform Development
Molecular intelligence platform architected as the shared foundation across every Kihealth diagnostic.
- Platform2026
Ki Intelligence Layer
AI-driven interpretive layer translating biomarker signals into structured clinical insight.
- Clinical2026
Beta Intercept™ T1D — Clinical Validation
Validation program advancing across clinical sites for Type 1 Diabetes interception.
- Clinical2026
Beta Intercept™ T2D — Clinical Validation
Parallel validation of the platform for Type 2 Diabetes therapeutic monitoring.
Targeted milestones ahead
- Clinical2026-2027
Expand Beta Intercept™ Validation
Grow enrollment and clinical-site footprint across T1D and T2D validation studies.
- Platform2026-2027
Scale Intercept IQ™ Across Applications
Extend platform capabilities into additional disease areas built on the same architecture.
- Commercial2026-2027
Commercial Deployment Expansion
Scale provider and health-system deployments of Beta Intercept™ diagnostics.
- Pipeline2027
Advance Oncology & Neurology Programs
Progress Onco Intercept™ and Neuro Intercept™ toward defined validation milestones.
- Geographic2027
Kihealth Europe Activation
Stand up Kihealth Europe operations and evaluate additional international geographies.
- Research2026-2027
Strategic Research Collaborations
Formalize additional academic, clinical, and industry research partnerships.
Forward-looking milestones represent current company objectives and are subject to scientific, clinical, regulatory, operational, and commercial considerations. They should not be interpreted as guarantees of future performance.
Building the operating system for the future of precision healthcare.
Request the corporate overview or speak with our investor relations team.
Kihealth is a privately held company. This page contains forward-looking statements regarding our platform, pipeline, regulatory plans, and financing activities. Actual results may differ materially.
Legal and Forward-Looking Statements
Last updated · November 18, 2026
The following disclosures apply to the Kihealth Labs Investor Relations pages and related materials. Language marked [COUNSEL REVIEW REQUIRED BEFORE PUBLICATION] is placeholder text pending final review by legal counsel.
The content on this website, including the Kihealth Labs Investor Relations pages, is provided for general corporate, educational, and informational purposes only. It is intended to describe the company, its scientific platform, its product programs, and its strategic direction, and is not intended to serve as investment, legal, medical, or tax advice.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Nothing on this website constitutes, or is intended to constitute, an offer to sell or a solicitation of an offer to buy any securities of Kihealth Labs or any affiliated entity, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Certain statements on this website concerning plans, objectives, milestones, market opportunities, product development, clinical validation, partnerships, commercialization, financial performance, and future performance constitute forward-looking statements. These statements are based on current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Certain products, diagnostics, technologies, biomarkers, algorithms, and applications described on this website may remain under active research, development, analytical or clinical validation, or regulatory review, and may not be available for clinical or commercial use in all jurisdictions or for all indications described.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Scientific, clinical, analytical, and regulatory outcomes are inherently uncertain and may differ materially from current expectations. Development, validation, regulatory, and commercialization timelines described on this website are targets only and are not guaranteed.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
References to products, programs, capabilities, indications, or future applications do not constitute a guarantee of regulatory clearance, authorization, or approval; successful launch; payer coverage or reimbursement; provider or patient adoption; or commercial availability in any specific market or timeframe.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Gated investor materials, including data room content, financial models, technical decks, and diligence documents, are confidential and may contain proprietary, trade-secret, or otherwise sensitive information. Access may be conditioned on execution of a confidentiality or non-disclosure agreement and on additional eligibility or verification requirements.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
Any securities that may be offered by Kihealth or its affiliates may be offered only pursuant to an applicable exemption from registration under U.S. federal and state securities laws and comparable non-U.S. laws, and only to investors who meet the applicable eligibility and qualification standards. Access to certain investor materials may be subject to verification of investor status.
[COUNSEL REVIEW REQUIRED BEFORE PUBLICATION]
These disclosures are provided in addition to, and do not supersede, the Terms of Use, Privacy Policy, and Disclaimer that govern this website. In the event of any conflict, the definitive legal documents executed between Kihealth Labs and a counterparty control.